UNC Hospitals is one of 378 facilities in the world, and among only 6 percent of all U.S. hospitals, that have earned Magnet designation.
Organization will receive The Artist in Residence Program to help people affected by cancer
G-Zero Therapeutics funded under Qualifying Therapeutic Discovery Project
In a study published this month in the Journal of Clinical Oncology, the results of a clinical trial of the drug bevacizumab to treat colon cancer in combination with the standard therapy found that the drug did not significantly increase disease-free survival in patients with stage II and stage III colon cancer.
Cell signaling protein may hold key to blocking long-studied genetic mutation